4 полученные результаты
Mafosfamide-cyclohexylamine is a new oxazaphosphorine derivative. It was chosen for phase-I clinical testing because of an expected higher therapeutic index and lack of complete cross resistance in animal tumors compared to cyclophosphamide. The schedule consisted of a single iv dose repeated every
The inhibitory effects of mafosfamide lysine, ASTA-Z 7654 (ASTA-Z) and etoposide, (VP16-213) on human leukemic progenitor cells (AML-CFU) were studied using a clonogenic assay. AML-CFU were shown to be less sensitive than human promyelocytic leukemia cells (HL-60) to the toxic effects of these two
Cyclophosphamide derivatives for in vitro use, such as mafosphamide L lysine (ASTA-Z 7654) are capable of removing residual leukaemic cells from the bone marrow used for autologous transplantation. ASTA-Z also removes committed stem cells detected in semi-solid cultures (CFU-GM). However,
AstA (alternative sulfate transporter) belongs to a large, but poorly characterized, Dal5 family of allantoate permeases of the Major Facilitator Superfamily. The astA gene has been cloned from an IAM 2006 Japanese strain of Aspergillus nidulans by complementation of a sulfate permease-deficient